Meiwu Technology Co LtdWNW

Meiwu Technology Co Ltd (WNW) closed 2025 with $7.1 million in revenue, which puts the company somewhere between a niche skincare brand and a corner-shop chemist that also happens to trade across East Asia. The same 20-F filing shows a net loss of $18.6 million and negative operating income of $8.8 million, so the revenue line is less ‘global platform’ and more ‘lipstick on a piggybank.’ The cash and equivalents balance was $17.9 million at year-end, giving the balance sheet a brief moment of dignity before the next quarter’s payroll and inventory bills arrive.

Meiwu’s public story is built around a ‘platform’ that integrates R&D, packaging, promotion, and sales of functional skincare products, plus a retail-store talent training arm. The company’s product rail is a single page on the Chinese-language site showing bottles of what appear to be serum and cream, complete with a stock-image-style photograph taken in a vaguely clinical setting. The page lists ‘beauty skincare’ as the category and links to a newsroom that is heavy on MOUs and light on audited revenue per SKU. The evidence does not show any regulatory approvals, clinical trial data, or audited sales per product.

The company’s most concrete operating metrics in the 20-F are the top-line number of $7.1 million, the $18.6 million net loss, and $9.0 million in net cash provided by operating activities for the year. R&D expense was $2.7 million, and the inventory balance at year-end was $82,820-small enough to fit in a single carton, large enough to remind readers that the company sells physical goods. Diluted EPS was negative $0.82 on 22.1 million weighted average diluted shares. Total assets were $50.7 million against $1.3 million in liabilities, leaving $49.4 million in shareholders’ equity.

The company’s regional exchange and the SEC filings are the primary source rails here. The latest 20-F was filed on 17 April 2026 and covers the year ended 31 December 2025. The WNW product/news site shows a serum bottle image and press releases about an MOU with Real BioTech (Qingdao) Ltd and a strategic cooperation with Shenzhen Zhinuowei Chuang Technology Co Ltd, both dated late 2025 and early 2026. The site does not publish audited product-level revenue, clinical data, or customer counts.

The reverse share split announced on 11 May 2026 is the most visible recent corporate action. The split reduces the share count from roughly 2,210 million to 22.1 million, pushing the quoted price from sub-penny to something that can trade without an immediate delisting flag. The company also announced a $14 million registered direct offering in early 2026, which would materially strengthen the cash position if completed. Neither filing specifies the use of proceeds beyond ‘general corporate purposes.’

The MOU with Real BioTech (Qingdao) Ltd promises cooperation on ‘beauty solutions utilizing marine active ingredients,’ a segment the company calls ‘high-growth.’ The MOU is explicitly non-binding and contains no delivery milestones or financial commitments. The company’s product page shows a serum bottle image but does not provide audited sales data, regulatory approvals, or clinical evidence. The site’s newsroom is rich in MOUs and light on audited revenue per SKU.